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GENETIC MARKERS FOR IMPROVED 
DISEASE RESISTANCE IN ANIMALS (BPI) 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This application claims bene?t under 35 U.S.C. § 119(e) 
of provisional application 60/294,668 ?led May 31, 2001. 
GRANT REFERENCE 
Work for this invention Was funded in part by ISU Grant 
No. 400-43-71-21-3337. The Government may have certain 
rights in this invention. 
FIELD OF THE INVENTION 
This invention relates generally to the detection of genetic 
differences among animals. More particularly, the invention 
relates to genetic markers Which have been identi?ed in 
several genes indicative of heritable phenotypes associated 
With improved traits, such as disease resistance or perfor 
mance. Methods and compositions for use of these markers 
in genotyping of animals and selection are also disclosed. 
BACKGROUND OF THE INVENTION 
Genetic differences exist among individual animals as 
Well as among breeds Which can be exploited by breeding 
techniques to achieve animals With desirable characteristics. 
For example, Chinese pig breeds are known for reaching 
puberty at an early age and for their large litter siZe, While 
American breeds are knoWn for their greater groWth rates 
and leanness. Often, hoWever, heritability for desired traits 
is loW, and standard breeding methods Which select indi 
viduals based upon phenotypic variations do not take fully 
into account genetic variability or complex gene interactions 
Which exist. 
There is a continuing need for an approach that deals With 
selection for disease resistance at the cellular or DNA level. 
This method Will provide the ability to genetically evaluate 
animals and to enable breeders to more accurately select 
those animals Which not only phenotypically express desir 
able traits but those Which express favorable underlying 
genetic criteria. This has largely been accomplished to date 
by marker-assisted selection. 
RFLP analysis has been used by several groups to study 
pig DNA. Jung et al., Theor. Appl. Genet., 77:271*274 
(1989), incorporated herein by reference, discloses the use 
of RFLP techniques to shoW genetic variability betWeen tWo 
pig breeds. Polymorphism Was demonstrated for sWine 
leukocyte antigen (SLA) Class I genes in these breeds. 
Hoganson et al., Abstract for Annual Meeting of MidWestern 
Section of the American Society of Animal Science, Mar. 
26428, 1990, incorporated herein by reference, reports on 
the polymorphism of sWine major histocompatibility com 
plex (MHC) genes for Chinese pigs, also demonstrated by 
RFLP analysis. Jung et al. Animal Genetics, 26:79*91 
(1989), incorporated herein by reference, reports on RFLP 
analysis of SLA Class I genes in certain boars. The authors 
state that the results suggest that there may be an association 
betWeen sWine SLA/MHC Class I genes and production and 
performance traits. They further state that the use of SLA 
Class I restriction fragments, as genetic markers, may have 
potential in the future for improving pig groWth perfor 
mance. 
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The ability to folloW a speci?c favorable genetic allele 
involves a novel and lengthy process of the identi?cation of 
a DNA molecular marker for a major effect gene. The 
marker may be linked to a single gene With a major effect or 
linked to a number of genes With additive effects. DNA 
markers have several advantages; segregation is easy to 
measure and is unambiguous, and DNA markers are co 
dominant, i.e., heterozygous and homoZygous animals can 
be distinctively identi?ed. Once a marker system is estab 
lished, selection decisions could be made very easily, since 
DNA markers can be assayed any time after a tissue or blood 
sample can be collected from the individual infant animal, or 
even an embryo. 
The use of genetic differences in receptor genes has 
become a valuable marker system for selection. For 
example, US. Pat. Nos. 5,550,024 and 5,374,526, issued to 
Rothschild et al., disclose a polymorphism in the pig estro 
gen receptor gene Which is associated With larger litter siZe, 
the disclosure of Which is incorporated herein by reference. 
US. Pat. No. 5,935,784 discloses polymorphic markers in 
the pig prolactin receptor gene Which are associated With 
larger litter siZe and overall reproductive ef?ciency, the 
disclosure of Which is incorporated herein by reference. 
The present invention provides a genetic markers, based 
upon the discovery of a polymorphisms in the porcine BPI 
gene, Which correlate With resistance or susceptibility to 
pathogenic infection in pigs. This Will permit genetic typing 
of pigs for their BPI allele and for determination of the 
relationship of speci?c RFLPs to resistance to infection. It 
Will also permit the identi?cation of individual males and 
females that carry the gene for improved resistance. Thus, 
the markers may be selection tools in breeding programs to 
develop lines and breeds that produce litters containing more 
resistant offspring. Also disclosed are novel porcine BPIP 
genomic sequences, as Well as primers for assays to identify 
the presence or absence of marker alleles. 
According to the invention a polymorphism Was identi 
?ed in the BPI gene Which is associated With the improved 
resistance to pathogenic infection. 
It is an object of the invention to provide a method of 
screening pigs to determine those more likely to produce 
o?fspring With improved pathogenic resistance, in the BPI 
gene. 
Another object of the invention is to provide a method for 
identifying genetic markers for improved disease resistance. 
A further object of the invention is to provide genetic 
markers for selection and breeding to obtain pigs that Will be 
expected to have a loWer susceptibility to infection than 
those Without the favorable allele. 
Yet another object of the invention is to provide a kit for 
evaluating a sample of pig DNA for speci?c genetic markers 
of disease resistance. 
Additional objects and advantages of the invention Will be 
set forth in part in the description that folloWs, and in part 
Will be obvious from the description, or may be learned by 
the practice of the invention. The objects and advantages of 
the invention Will be attained by means of the instrumen 
tality’s and combinations particularly pointed out in the 
appended claims. 
SUMMARY OF THE INVENTION 
To achieve the objects and in accordance With the purpose 
of the invention, as embodied and broadly described herein, 
the present invention provides a method for screening ani 
mals to determine those more likely to have bene?cial 
phenotypes or against those With deleterious phenotypes 
US 7,070,929 B2 
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(such as, or associated With, improved innate immunity, 
disease resistance or resistance to bacterial infection, as 
evidenced by bacterial count, lymphocyte count, neutrophil 
count, or monocyte count after challenge to identify animals 
Which have superior bacterial killing, or ability to stave off 
infection in a particular population, When bred, or raised or 
to select against pigs Which have alleles indicating unfavor 
able phenotypes. These traits may also be observed by 
assaying general indicia of overall health of the animal. As 
used herein the term “biologically different disease resis 
tance” or “innate immunity” shall mean an ability to stave 
off infection that is superior to that Which is observed When 
the favorable allele is not present as evidenced by indicia 
including but not limited to average lymphocyte count and 
percentage, monocyte count, neutrophil count and percent 
age and bacterial count after challenge or other measure 
ments of innate immunity as Well as measurements of 
overall health of the animal such as feed intake, Weight gain 
and the like. 
Thus, the present invention provides a method for screen 
ing pigs to determine those more likely to have the improved 
trait of superior disease resistance and/ or those less likely to 
demonstrate those traits Which method comprises the steps: 
1) obtaining a sample of tissue or genomic DNA from an 
animal; and 2) analyZing the mRNA or genomic DNA 
obtained in l) to determine Which allele(s) is/are present. 
Brie?y, the sample of genetic material analyZed to determine 
the presence or absence of a particular allele that is corre 
lated With a desirable trait, or one Which is linked thereto. 
As is Well knoWn to those of skill in the art, a variety of 
techniques may be utiliZed When comparing nucleic acid 
molecules for sequence differences. These include by Way of 
example, restriction fragment length polymorphism analy 
sis, heteroduplex analysis, single strand conformation poly 
morphism analysis, denaturing gradient electrophoresis and 
temperature gradient electrophoresis. 
In one embodiment, the polymorphism is a restriction 
fragment length polymorphism and the assay comprises 
identifying the gene from isolated genetic material; exposing 
the gene to a restriction enZyme that yields restriction 
fragments of the gene of varying length; separating the 
restriction fragments to form a restriction pattern, such as by 
electrophoresis or HPLC separation; and comparing the 
resulting restriction fragment pattern from an animal gene 
that is either knoWn to have or not to have the desired 
marker. If an animal tests positive for the marker (or allele), 
such animal can be considered for inclusion in the breeding 
program. If the animal does not test positive for the marker 
genotype, the animal can be culled from the group and 
otherWise used. 
In a most preferred embodiment, the gene, or a fragment 
thereof, is isolated by the use of primers and DNA poly 
merase to amplify a speci?c region of the gene Which 
contains the polymorphism or a polymorphism linked 
thereto. Next, the ampli?ed region is either directly sepa 
rated or sequenced or is digested With a restriction enZyme 
and fragments are again separated. Visualization of the 
separated fragments, or RFLP pattern, is by simple staining 
of the fragments, or by labeling the primers or the nucleoside 
triphosphates used in ampli?cation. 
In another embodiment, the invention comprises a method 
for identifying a genetic marker for disease resistance traits, 
such as bacterial counts, lymphocyte count, neutrophil 
count, or monocyte count after challenge. Male and female 
animals of the same breed, breed cross, or similar genetic 
lineage are bred, and the disease resistance traits are deter 
mined. A polymorphism in the gene of each animal is 
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identi?ed and associated With the desired trait(s). Preferably, 
PCR-RFLP analysis is used to determine the polymorphism. 
It is also possible to establish linkage betWeen speci?c 
alleles of alternative DNA markers and alleles of DNA 
markers knoWn to be associated With a particular gene (e. g., 
the BPI gene discussed herein) Which have previously been 
shoWn to be associated With a particular trait. Thus, in the 
present situation, taking a particular gene, it Would be 
possible, at least in the short term, to select for pigs, or other 
animals, likely to have superior disease resistance or ability 
to stave off infection, or alternatively, against pigs likely to 
have inferior traits, indirectly, by selecting for certain alleles 
of a particular gene associated With the marker alleles 
through the selection of speci?c linked alleles of alternative 
chromosome markers. Thus, in the present situation, taking 
the BPI gene, it Would be possible, at least in the short term, 
to select for pigs likely to produce disease resistance, or 
alternatively, against pigs likely to produce susceptible lit 
ters indirectly, by selecting for certain alleles of the BPI 
associated marker through the selection of speci?c alleles of 
alternative markers located on the same chromosome BPI is. 
The invention further comprises a kit for evaluating a 
sample of DNA for the presence in genetic material of a 
desired genetic marker located in the gene indicative of a 
inheritable trait of disease resistance or ability to stave off 
infection. At a minimum, the kit is a container With one or 
more reagents that identify a polymorphism in the porcine 
BPI gene. Preferably, the reagent is a set of oligonucleotide 
primers capable of amplifying a fragment of the selected 
gene that contains a polymorphism. Preferably, the kit 
further contains a restriction enZyme that cleaves the gene in 
at least one place, allowing for separation of fragments and 
detection of polymorphic loci. 
In another embodiment, the invention comprises a method 
for identifying a genetic marker for meat quality and/or 
groWth in a particular population. Male and female pigs of 
the same breed or breed cross or similar genetic lineage are 
bred, and meat quality and/or groWth produced by each pig 
is determined. A polymorphism in the BPI gene of each pig 
is identi?ed and associated With the meat quality and/or 
groWth. Preferably, RFLP analysis is used to determine the 
polymorphism. 
In another embodiment, the invention comprises a method 
for identifying a genetic marker for meat quality and/or 
groWth in any particular economic animal other than a pig. 
Based upon the highly conserved nature of this gene among 
different animals and the location of the polymorphisms 
Within these highly conserved regions, is it expected that 
With no more than routine testing as described herein this 
marker can be applied to different animal species to select 
for meat quality and/or groWth based on the teachings 
herein. Male and female animals of the same breed or breed 
cross or similar genetic lineage are bred, and the meat 
quality and/or groWth produced by each animal is deter 
mined and correlated. For other animals in Which sequences 
are available a BLAST comparison of sequences may be 
used to ascertain Whether the particular allele is analogous to 
the one disclosed herein. The analogous polymorphism Will 
be present in other animals and in other closely related 
genes. The term “analogous polymorphism” shall be a 
polymorphism Which is the same as any of those disclosed 
herein as determined by BLAST comparisons. 
The folloWing terms are used to describe the sequence 
relationships betWeen tWo or more nucleic acids or poly 
nucleotides: (a) “reference sequence”, (b) “comparison Win 
doW”, (c) “sequence identity”, (d) “percentage of sequence 
identity”, and (e) “substantial identity”. 
US 7,070,929 B2 
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(a) As used herein, “reference sequence” is a de?ned 
sequence used as a basis for sequence comparison. In this 
case the Reference BPI sequence. A reference sequence may 
be a subset or the entirety of a speci?ed sequence; for 
example, as a segment of a full-length cDNA or gene 
sequence, or the complete cDNA or gene sequence. 
(b) As used herein, “comparison WindoW” includes ref 
erence to a contiguous and speci?ed segment of a poly 
nucleotide sequence, Wherein the polynucleotide sequence 
may be compared to a reference sequence and Wherein the 
portion of the polynucleotide sequence in the comparison 
WindoW may comprise additions or deletions (i.e., gaps) 
compared to the reference sequence (Which does not com 
prise additions or deletions) for optimal alignment of the tWo 
sequences. Generally, the comparison WindoW is at least 20 
contiguous nucleotides in length, and optionally can be 30, 
40, 50, 100, or longer. Those of skill in the art understand 
that to avoid a high similarity to a reference sequence due to 
inclusion of gaps in the polynucleotide sequence, a gap 
penalty is typically introduced and is subtracted from the 
number of matches. 
Methods of alignment of sequences for comparison are 
Well-knoWn in the art. Optimal alignment of sequences for 
comparison may be conducted by the local homology algo 
rithm of Smith and Waterman, Adv. Appl. Math. 2:482 
(1981); by the homology alignment algorithm of Needleman 
and Wunsch, J. Mol. Biol. 48:443 (1970); by the search for 
similarity method of Pearson and Lipman, Proc. Natl. Acad. 
Sci. 85:2444 (1988); by computeriZed implementations of 
these algorithms, including, but not limited to: CLUSTAL in 
the PC/Gene program by lntelligenetics, Mountain View, 
Calif.; GAP, BESTFIT, BLAST, FASTA, and TFASTA in the 
Wisconsin Genetics SoftWare Package, Genetics Computer 
Group (GCG), 575 Science Dr., Madison, Wis., USA; the 
CLUSTAL program is Well described by Higgins and Sharp, 
Gene 73:237i244 (1988); Higgins and Sharp, CABIOS 
5:151*153 (1989); Corpet, et al., Nucleic Acids Research 
16:10881*90 (1988); Huang, et al., Computer Applications 
in the Biosciences 8:155*65 (1992), and Pearson, et al., 
Methods in Molecular Biology 24:307i33l (1994). The 
BLAST family of programs Which can be used for database 
similarity searches includes: BLASTN for nucleotide query 
sequences against nucleotide database sequences; BLASTX 
for nucleotide query sequences against protein database 
sequences; BLASTP for protein query sequences against 
protein database sequences; TBLASTN for protein query 
sequences against nucleotide database sequences; and 
TBLASTX for nucleotide query sequences against nucle 
otide database sequences. See, Current Protocols in Molecu 
lar Biology, Chapter 19, Ausubel, et al., Eds., Greene 
Publishing and Wiley-lnterscience, NeW York (1995). 
Unless otherWise stated, sequence identity/similarity val 
ues provided herein refer to the value obtained using the 
BLAST 2.0 suite of programs using default parameters. 
Altschul et a., Nucleic Acids Res. 25:3389i3402 (1997). 
SoftWare for performing BLAST analyses is publicly avail 
able, e.g., through the National Center for Biotechnology 
lnformation (http://WWW.ncbi.nlm.nih.gov/). 
This algorithm involves ?rst identifying high scoring 
sequence pairs (HSPs) by identifying short Words of length 
W in the query sequence, Which either match or satisfy some 
positive-valued threshold score T When aligned With a Word 
of the same length in a database sequence. T is referred to 
as the neighborhood Word score threshold (Altschul et al., 
supra). These initial neighborhood Word hits act as seeds for 
initiating searches to ?nd longer HSPs containing them. The 
Word hits are then extended in both directions along each 
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sequence for as far as the cumulative alignment score can be 
increased. Cumulative scores are calculated using, for nucle 
otide sequences, the parameters M (reWard score for a pair 
of matching residues; alWays >0) and N (penalty score for 
mismatching residues; alWays <0). For amino acid 
sequences, a scoring matrix is used to calculate the cumu 
lative score. Extension of the Word hits in each direction are 
halted When: the cumulative alignment score falls off by the 
quantity X from its maximum achieved value; the cumula 
tive score goes to Zero or beloW, due to the accumulation of 
one or more negative-scoring residue alignments; or the end 
of either sequence is reached. The BLAST algorithm param 
eters W, T, and X determine the sensitivity and speed of the 
alignment. The BLASTN program (for nucleotide 
sequences) uses as defaults a Wordlength (W) of 11, an 
expectation (E) of 10, a cutoff of 100, M:5, N:—4, and a 
comparison of both strands. For amino acid sequences, the 
BLASTP program uses as defaults a Wordlength (W) of 3, an 
expectation (E) of 10, and the BLOSUM62 scoring matrix 
(see Henikolf & Henikolf (1989) Proc. Natl. Acad. Sci. USA 
89: 1091 5). 
In addition to calculating percent sequence identity, the 
BLAST algorithm also performs a statistical analysis of the 
similarity betWeen tWo sequences (see, e.g., Karlin & Alts 
chul, Proc. Natl. Acad. Sci. USA 90:5873i5787 (1993)). 
One measure of similarity provided by the BLAST algo 
rithm is the smallest sum probability (P(N)), Which provides 
an indication of the probability by Which a match betWeen 
tWo nucleotide or amino acid sequences Would occur by 
chance. 
BLAST searches assume that proteins can be modeled as 
random sequences. HoWever, many real proteins comprise 
regions of nonrandom sequences Which may be homopoly 
meric tracts, short-period repeats, or regions enriched in one 
or more amino acids. Such loW-complexity regions may be 
aligned betWeen unrelated proteins even though other 
regions of the protein are entirely dissimilar. A number of 
loW-complexity ?lter programs can be employed to reduce 
such loW-complexity alignments. For example, the SEG 
(Wooten and Federhen, Comput. Chem., 17:149*163 
(1993)) and XNU (Clayerie and States, Comput. Chem., 
17: 1914201 (1993)) loW-complexity ?lters can be employed 
alone or in combination. 
(c) As used herein, “sequence identity” or “identity” in the 
context of tWo nucleic acid or polypeptide sequences 
includes reference to the residues in the tWo sequences 
Which are the same When aligned for maximum correspon 
dence over a speci?ed comparison WindoW. When percent 
age of sequence identity is used in reference to proteins it is 
recogniZed that residue positions Which are not identical 
often differ by conservative amino acid substitutions, Where 
amino acid residues are substituted for other amino acid 
residues With similar chemical properties (eg charge or 
hydrophobicity) and therefore do not change the functional 
properties of the molecule. Where sequences differ in con 
servative substitutions, the percent sequence identity may be 
adjusted upWards to correct for the conservative nature of 
the substitution. Sequences Which differ by such conserva 
tive substitutions are said to have “sequence similarity” or 
“similarity”. Means for making this adjustment are Well 
knoWn to those of skill in the art. Typically this involves 
scoring a conservative substitution as a partial rather than a 
full mismatch, thereby increasing the percentage sequence 
identity. Thus, for example, Where an identical amino acid is 
given a score of 1 and a non-conservative substitution is 
given a score of Zero, a conservative substitution is given a 
score betWeen Zero and 1. The scoring of conservative 
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substitutions is calculated, e.g., according to the algorithm of 
Meyers and Miller, Computer Applic. Biol. Sci., 4111417 
(1988) e.g., as implemented in the program PC/GENE 
(lntelligenetics, Mountain View, Calif., USA). 
(d) As used herein, “percentage of sequence identity” 
means the value determined by comparing tWo optimally 
aligned sequences over a comparison WindoW, Wherein the 
portion of the polynucleotide sequence in the comparison 
WindoW may comprise additions or deletions (i.e., gaps) as 
compared to the reference sequence (Which does not com 
prise additions or deletions) for optimal alignment of the tWo 
sequences. The percentage is calculated by determining the 
number of positions at Which the identical nucleic acid base 
or amino acid residue occurs in both sequences to yield the 
number of matched positions, dividing the number of 
matched positions by the total number of positions in the 
WindoW of comparison and multiplying the result by 100 to 
yield the percentage of sequence identity. 
(e)(l) The term “substantial identity” of polynucleotide 
sequences means that a polynucleotide comprises a 
sequence that has at least 70% sequence identity, preferably 
at least 80%, more preferably at least 90% and most pref 
erably at least 95%, compared to a reference sequence using 
one of the alignment programs described using standard 
parameters. One of skill Will recognize that these values can 
be appropriately adjusted to determine corresponding iden 
tity of proteins encoded by tWo nucleotide sequences by 
taking into account codon degeneracy, amino acid similarity, 
reading frame positioning and the like. Substantial identity 
of amino acid sequences for these purposes normally means 
sequence identity of at least 60%, or preferably at least 70%, 
80%, 90%, and most preferably at least 95%. 
These programs and algorithms can ascertain the analogy 
of a particular polymorphism in a target gene to those 
disclosed herein. It is expected that this polymorphism Will 
exist in other animals and use of the same in other animals 
than disclosed herein involved no more than routine opti 
mization of parameters using the teachings herein. 
It is also possible to establish linkage betWeen speci?c 
alleles of alternative DNA markers and alleles of DNA 
markers knoWn to be associated With a particular gene (eg 
the BPI gene discussed herein), Which have previously been 
shoWn to be associated With a particular trait. Thus, in the 
present situation, taking the BPI gene, it Would be possible, 
at least in the short term, to select for pigs likely to produce 
desired meat quality and/ or groWth, or alternatively against 
pigs likely to produce less desirable meat quality and/or 
groWth, indirectly, by selecting for certain alleles of a BPI 
associated marker through the selection of speci?c alleles of 
alternative chromosome markers. As used herein the term 
“genetic marker” shall include not only the polymorphism 
disclosed by any means of assaying for the protein changes 
associated With the polymorphism, be they linked markers, 
use of microsatellites, or even other means of assaying for 
the causative protein changes indicated by the marker and 
the use of the same to in?uence the meat quality and/or 
groWth of an animal. 
As used herein, often the designation of a particular 
polymorphism is made by the name of a particular restric 
tion enzyme. This is not intended to imply that the only Way 
that the site can be identi?ed is by the use of that restriction 
enzyme. There are numerous databases and resources avail 
able to those of skill in the art to identify other restriction 
enzymes Which can be used to identify a particular poly 
morphism, for example http://darWin.bio.geneseo.edu Which 
can give restriction enzymes upon analysis of a sequence 
and the polymorphism to be identi?ed. In fact as disclosed 
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in the teachings herein there are numerous Ways of identi 
fying a particular polymorphism or allele With alternate 
methods Which may not even include a restriction enzyme, 
but Which assay for the same genetic or proteomic altema 
tive form. 
In yet another embodiment of this invention novel porcine 
nucleotide sequences have been identi?ed and are disclosed 
Which encode porcine BPI. The cDNA of the porcine BPI 
gene as Well as some intronic DNA sequences are disclosed. 
These sequences may be used for the design of primers to 
assay for the SNP’s of the invention or for production of 
recombinant BPI. The invention is intended to include these 
sequences as Well as all conservatively modi?ed variants 
thereof as Well as those sequences Which Will hybridize 
under conditions of high stringency to the sequences dis 
closed. The term BPI as used herein shall be interpreted to 
include these conservatively modi?ed variants as Well as 
those hybridized sequences. 
The term “conservatively modi?ed variants” applies to 
both amino acid and nucleic acid sequences. With respect to 
particular nucleic acid sequences, conservatively modi?ed 
variants refers to those nucleic acids Which encode identical 
or conservatively modi?ed variants of the amino acid 
sequences. Because of the degeneracy of the genetic code, a 
large number of functionally identical nucleic acids encode 
any given protein. For instance, the codons GCA, GCC, 
GCG and GCU all encode the amino acid alanine. Thus, at 
every position Where an alanine is speci?ed by a codon, the 
codon can be altered to any of the corresponding codons 
described Without altering the encoded polypeptide. Such 
nucleic acid variations are “silent variations” and represent 
one species of conservatively modi?ed variation. Every 
nucleic acid sequence herein that encodes a polypeptide 
also, by reference to the genetic code, describes every 
possible silent variation of the nucleic acid. One of ordinary 
skill Will recognize that each codon in a nucleic acid (except 
AUG, Which is ordinarily the only codon for methionine; 
and UGG, Which is ordinarily the only codon for tryptophan) 
can be modi?ed to yield a functionally identical molecule. 
Accordingly, each silent variation of a nucleic acid Which 
encodes a polypeptide of the present invention is implicit in 
each described polypeptide sequence and is Within the scope 
of the present invention. 
As to amino acid sequences, one of skill Will recognize 
that individual substitutions, deletions or additions to a 
nucleic acid, peptide, polypeptide, or protein sequence 
Which alters, adds or deletes a single amino acid or a small 
percentage of amino acids in the encoded sequence is a 
“conservatively modi?ed variant” Where the alteration 
results in the substitution of an amino acid With a chemically 
similar amino acid. Thus, any number of amino acid residues 
selected from the group of integers consisting of from 1 to 
15 can be so altered. Thus, for example, 1, 2, 3, 4, 5, 7, or 
10 alterations can be made. Conservatively modi?ed vari 
ants typically provide similar biological activity as the 
unmodi?ed polypeptide sequence from Which they are 
derived. For example, substrate speci?city, enzyme activity, 
or ligand/receptor binding is generally at least 30%, 40%, 
50%, 60%, 70%, 80%, or 90% of the native protein for its 
native substrate. Conservative substitution tables providing 
functionally similar amino acids are Well knoWn in the art. 
The folloWing six groups each contain amino acids that 
are conservative substitutions for one another: 
1) Alanine (A), Serine (S), Threonine (T); 
2) Aspartic acid (D), Glutamic acid (E); 
3) Asparagine (N), Glutamine (Q); 
4) Arginine (R), Lysine (K); 
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5) Isoleucine (I), Leucine (L), Methionine (M), Valine 
(V); and 
6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W). 
See also, Creighton (1984) Proteins W.H. Freeman and 
Company. 
By “encoding” or “encoded”, With respect to a speci?ed 
nucleic acid, is meant comprising the information for trans 
lation into the speci?ed protein. A nucleic acid encoding a 
protein may comprise non-translated sequences (e.g., 
introns) Within translated regions of the nucleic acid, or may 
lack such intervening non-translated sequences (e.g., as in 
cDNA). The information by Which a protein is encoded is 
speci?ed by the use of codons. Typically, the amino acid 
sequence is encoded by the nucleic acid using the “univer 
sal” genetic code. HoWever, variants of the universal code, 
such as are present in some plant, animal, and fungal 
mitochondria, the bacterium Mycoplasma capricolum, or the 
ciliate Macronucleus, may be used When the nucleic acid is 
expressed therein. 
The term “stringent conditions” or “stringent hybridiza 
tion conditions” includes reference to conditions under 
Which a probe Will hybridize to its target sequence, to a 
detectably greater degree than to other sequences (e.g., at 
least 2-fold over background). Stringent conditions are 
sequence-dependent and be different in different circum 
stances. By controlling the stringency of the hybridization 
and/or Washing conditions, target sequences can be identi 
?ed Which are 100% complementary to the probe (homolo 
gous probing). Alternatively, stringency conditions can be 
adjusted to alloW some mismatching in sequences so that 
loWer degrees of similarity are detected (heterologous prob 
ing). Generally, a probe is less than about 1000 nucleotides 
in length, optionally less than 500 nucleotides in length. 
Typically, stringent conditions Will be those in Which the 
salt concentration is less than about 1.5 M Na ion, typically 
about 0.01 to 1.0 M Na ion concentration (or other salts) at 
pH 7.0 to 8.3 and the temperature is at least about 30° C. for 
short probes (e.g., 10 to 50 nucleotides) and at least about 
60° C. for long probes (e.g., greater than 50 nucleotides). 
Stringent conditions may also be achieved With the addition 
of destabilizing agents such as formamide. Exemplary loW 
stringency conditions include hybridization With a buffer 
solution of 30 to 35% formamide, 1 M NaCl, 1% SDS 
(sodium dodecyl sulphate) at 37° C., and a Wash in 1x to 2x 
SSC (20><SSC:3.0 M NaC1/0.3 M trisodium citrate) at 50 to 
55° C. Exemplary moderate stringency conditions include 
hybridization in 40 to 45% formamide, 1 M NaCl, 1% SDS 
at 37° C., and a Wash in 0.5>< to 1><SSC at 55 to 50° C. 
Exemplary high stringency conditions include hybridization 
in 50% formamide, 1 M NaCl, 1% SDS at 37° C., and a 
Wash in 0.1><SSC at 60 to 65° C. 
Speci?city is typically the function of post-hybridization 
Washes, the critical factors being the ionic strength and 
temperature of the ?nal Wash solution. For DNA-DNA 
hybrids, the Tm can be approximated from the equation of 
Meinkoth and Wahl, Anal. Biochem., 13812674284 (1984): 
Tm:81.5° C.+16.6 (log M)+0.41 (% GC)—0.61 (% form) 
500/L; Where M is the molarity of monovalent cations, % 
GC is the percentage of guanosine and cytosine nucleotides 
in the DNA, % form is the percentage of formamide in the 
hybridization solution, and L is the length of the hybrid in 
base pairs. The Tm is the temperature (under de?ned ionic 
strength and pH) at Which 50% of the complementary target 
sequence hybridizes to a perfectly matched probe. Tm is 
reduced by about 1° C. for each 1% of mismatching; thus, 
Tm, hybridization and/or Wash conditions can be adjusted to 
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hybridize to sequences of the desired identity. For example, 
if sequences With 290% identity are sought, the Tm can be 
decreased 10° C. Generally, stringent conditions are selected 
to be about 5° C. loWer than the thermal melting point (Tm) 
for the speci?c sequence and its complement at a de?ned 
ionic strength and pH. HoWever, severely stringent condi 
tions can utilize a hybridization and/ or Wash at 1, 2, 3, or 4° 
C. loWer than the thermal melting point (Tm); moderately 
stringent conditions can utilize a hybridization and/or Wash 
at 6, 7, 8, 9, or 10° C. loWer than the thermal melting point 
(Tm); loW stringency conditions can utilize a hybridization 
and/or Wash at 11, 12, 13, 14, 15, or 20° C. loWer than the 
thermal melting point (Tm) Using the equation, hybridiza 
tion and Wash compositions, and desired Tm, those of 
ordinary skill Will understand that variations in the strin 
gency of hybridization and/ or Wash solutions are inherently 
described. If the desired degree of mismatching results in a 
Tm of less than 45° C. (aqueous solution) or 32° C. (forma 
mide solution) it is preferred to increase the SSC concen 
tration so that a higher temperature can be used. An exten 
sive guide to the hybridization of nucleic acids is found in 
Tijssen, Laboratory Techniques in Biochemistry and 
Molecular Biology-Hybridization With Nucleic Acids 
Probes, Part I, Chapter 2, Ausubel, et al., Eds., Greene 
Publishing and Wiley-Interscience, NeW York (1995). 
DETAILED DESCRIPTION FO THE FIGURES 
FIG. 1 is the sequence (SEQ ID NO:3) of the region 
ampli?ed by primers 1 and 2. Bold text are exon 4 sequences 
and regular text are intron sequences. RIA or G. Ava II 
polymorphism is at position 103. 
FIG. 2 is the sequence (SEQ ID NO:6) of the region 
ampli?ed by primers 3 and 4. Bold text are exon 10 
sequences and regular text are intron sequences, KIG or T. 
FIG. 3 is the sequence (SEQ ID NO:8) ampli?ed by 
primers 7 and 8. Bold text are exon 10 and exon 11 
sequences and regular text are intron sequences, III repre 
sents about 300 bp insertion present in alternate allele. This 
inserted sequence is a repetitive region that is dif?cult to 
sequence accurately. 
FIGS. 4(aw) and 5(aib) are a comparison of the full 
length coding region sequence of porcine BPI and alignment 
of full-length sequence of each allele (3,4) at the DNA level 
(4) and the protein level (5). Differences in base pair 
sequence are in bold and underlined. 1 porcine a3 (SEQ ID 
NO: 11); 2 porcine a4 (SEQ ID NO: 12); 3 human BPI (SEQ 
ID NO: 13); 4 human LBP (SEQ ID NO: 14); 5 human PLTP 
(SEQ ID NO:15); 6 human CETP (SEQ ID NO:16). 
DETAILED DESCRIPTION OF THE 
INVENTION 
Reference Will noW be made in detail to the presently 
preferred embodiments of the invention, Which together 
With the folloWing examples, serve to explain the principles 
of the invention. All references cited herein are hereby 
expressly incorporated by reference. 
The invention relates to the identi?cation of quantitative 
trait loci (QTL) for improved disease resistance or resistance 
to pathogen infection, including, but not limited to, Salmo 
nellosis, identi?able by traits such as bacterial count, total or 
speci?c leukocyte counts (including White blood cells, lym 
phocytes, monocytes, neutrophils) before and/or after infec 
tion, or leukocyte function to identify pigs and other animals 
Which have superior pathogen killing or ability to stave off 
infection. It provides a method of screening animals to 
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determine those more likely to have improved resistance 
and/or good immune system and overall health traits (as 
shoWn by measures such as Weight gain or feed efficiency) 
When bred by identifying the presence or an absence of a 
polymorphism in certain genes (BPI) that are correlated With 
these traits. 
In one embodiment the invention relates to novel BPI 
alleles characteriZed by a polymorphisms in exon 4, intron 
l0 and exon 10 Which are correlated With improved disease 
resistance and/or innate immunity. The presence a particular 
allele may be identi?ed in one embodiment by the use of the 
restriction enzymes Ava II or Hpa II. 
Thus, the invention relates to genetic markers and meth 
ods of identifying those markers in a pig or other animal of 
a particular breed, strain, population, or group, Whereby an 
animal has disease resistance above the mean for that 
particular breed, strain, population, or group. 
The marker may be identi?ed by any method knoWn to 
one of ordinary skill in the art Which identi?es the presence 
or absence of the particular allele or marker, including, for 
example, direct sequencing single-strand conformation 
polymorphism analysis (SSCP), base excision sequence 
scanning (BESS), RFLP analysis, heteroduplex analysis, 
denaturing gradient gel electrophoresis, allelic PCR, tem 
perature gradient electrophoresis, ligase chain reaction, 
direct sequencing, minisequencing, nucleic acid hybridiza 
tion, and micro-array-type detection of the BPI gene, or 
other linked sequences, and examination for a polymorphic 
site. Yet another technique includes an Invader Assay Which 
includes isothermic ampli?cation that relies on a catalytic 
release of ?uorescence. See Third Wave Technology at 
WWW.tWt.com. All of these techniques are intended to be 
Within the scope of the invention. The markers may also be 
assayed for by identifying correlating changes in amino 
acids encoded by the sequences herein. 
A Brief Description of these Techniques FolloWs. 
Isolation and Ampli?cation of Nucleic Acid 
Samples of patient, proband, test subject, or family mem 
ber genomic DNA are isolated from any convenient source 
including saliva, buccal cells, hair roots, blood, cord blood, 
amniotic ?uid, interstitial ?uid, peritoneal ?uid, chorionic 
villus, and any other suitable cell or tissue sample With intact 
interphase nuclei or metaphase cells. The cells can be 
obtained from solid tissue as from a fresh or preserved organ 
or from a tissue sample or biopsy. The sample can contain 
compounds Which are not naturally intermixed With the 
biological material such as preservatives, anticoagulants, 
bu?‘ers, ?xatives, nutrients, antibiotics, or the like. 
Methods for isolation of genomic DNA from these vari 
ous sources are described in, for example, Kirby, DNA 
Fingerprinting, An Introduction, W. H. Freeman & Co. NeW 
York (1992). Genomic DNA can also be isolated from 
cultured primary or secondary cell cultures or from trans 
formed cell lines derived from any of the aforementioned 
tissue samples. 
Samples of patient, proband, test subject or family mem 
ber RNA can also be used. RNA can be isolated from tissues 
expressing the BPI gene as described in Sambrook et al., 
supra. RNA can be total cellular RNA, mRNA, poly A+ 
RNA, or any combination thereof. For best results, the RNA 
is puri?ed, but can also be unpuri?ed cytoplasmic RNA. 
RNA can be reverse transcribed to form DNA Which is then 
used as the ampli?cation template, such that the PCR 
indirectly ampli?es a speci?c population of RNA transcripts. 
20 
25 
30 
35 
40 
45 
50 
55 
60 
65 
12 
See, e.g., Sambrook, supra, Kawasaki et al., Chapter 8 in 
PCR Technology, (1992) supra, and Berg et al., Hum. Genet. 
8516554658 (1990). 
PCR Ampli?cation 
The most common means for ampli?cation is polymerase 
chain reaction (PCR), as described in US. Pat. Nos. 4,683, 
195, 4,683,202, 4,965,188 each of Which is hereby incor 
porated by reference. If PCR is used to amplify the target 
regions in blood cells, hepariniZed Whole blood should be 
draWn in a sealed vacuum tube kept separated from other 
samples and handled With clean gloves. For best results, 
blood should be processed immediately after collection; if 
this is impossible, it should be kept in a sealed container at 
4° C. until use. Cells in other physiological ?uids may also 
be assayed. When using any of these ?uids, the cells in the 
?uid should be separated from the ?uid component by 
centrifugation. 
Tissues should be roughly minced using a sterile, dispos 
able scalpel and a sterile needle (or tWo scalpels) in a 5 mm 
Petri dish. Procedures for removing paraf?n from tissue 
sections are described in a variety of specialiZed handbooks 
Well knoWn to those skilled in the art. 
To amplify a target nucleic acid sequence in a sample by 
PCR, the sequence must be accessible to the components of 
the ampli?cation system. One method of isolating target 
DNA is crude extraction Which is useful for relatively large 
samples. Brie?y, mononuclear cells from samples of blood, 
amniocytes from amniotic ?uid, cultured chorionic villus 
cells, or the like are isolated by layering on sterile Ficoll 
Hypaque gradient by standard procedures. Interphase cells 
are collected and Washed three times in sterile phosphate 
bu?‘ered saline before DNA extraction. If testing DNA from 
peripheral blood lymphocytes, an osmotic shock (treatment 
of the pellet for 10 sec With distilled Water) is suggested, 
folloWed by tWo additional Washings if residual red blood 
cells are visible folloWing the initial Washes. This Will 
prevent the inhibitory e?‘ect of the heme group carried by 
hemoglobin on the PCR reaction. If PCR testing is not 
performed immediately after sample collection, aliquots of 
106 cells can be pelleted in sterile Eppendorf tubes and the 
dry pellet frozen at —20° C. until use. 
The cells are resuspended (l06 nucleated cells per 100 pl) 
in a bu?er of 50 mM Tris-HCl (pH 8.3), 50 mM KCl 1.5 mM 
MgCl2, 0.5% TWeen 20, 0.5% NP40 supplemented With 100 
ug/ml of proteinase K. After incubating at 56° C. for 2 hr. the 
cells are heated to 95° C. for 10 min to inactivate the 
proteinase K and immediately moved to Wet ice (snap-cool). 
If gross aggregates are present, another cycle of digestion in 
the same bu?er should be undertaken. Ten pl of this extract 
is used for ampli?cation. 
When extracting DNA from tissues, e.g., chorionic villus 
cells or con?uent cultured cells, the amount of the above 
mentioned bu?er With proteinase K may vary according to 
the siZe of the tissue sample. The extract is incubated for 
4410 hrs at 50°i60° C. and then at 95° C. for 10 minutes to 
inactivate the proteinase. During longer incubations, fresh 
proteinase K should be added after about 4 hr at the original 
concentration. 
When the sample contains a small number of cells, 
extraction may be accomplished by methods as described in 
Higuchi, “Simple and Rapid Preparation of Samples for 
PCR”, in PCR Technology, Ehrlich, H. A. (ed.), Stockton 
Press, NeW York, Which is incorporated herein by reference. 
PCR can be employed to amplify target regions in very small 
numbers of cells (100045000) derived from individual colo 
nies from bone marroW and peripheral blood cultures. The 
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cells in the sample are suspended in 20 pl of PCR lysis buffer 
(10 mM Tris-HCl (pH 8.3), 50 mM KCl, 2.5 mM MgCl2, 0.1 
mg/ml gelatin, 0.45% NP40, 0.45% TWeen 20) and frozen 
until use. When PCR is to be performed, 0.6 pl of proteinase 
K (2 mg/ml) is added to the cells in the PCR lysis buffer. The 
sample is then heated to about 60° C. and incubated for 1 hr. 
Digestion is stopped through inactivation of the proteinase K 
by heating the samples to 95° C. for 10 min and then cooling 
on ice. 
A relatively easy procedure for extracting DNA for PCR 
is a salting out procedure adapted from the method described 
by Miller et al., Nucleic Acids Res. 16:1215 (1988), Which 
is incorporated herein by reference. Mononuclear cells are 
separated on a Ficoll-Hypaque gradient. The cells are resus 
pended in 3 ml of lysis buffer (10 mM Tris-HCl, 400 mM 
NaCl, 2 mM Na2 EDTA, pH 8.2). Fifty pl of a 20 mg/ml 
solution of proteinase K and 150 pl of a 20% SDS solution 
are added to the cells and then incubated at 37° C. overnight. 
Rocking the tubes during incubation Will improve the diges 
tion of the sample. If the proteinase K digestion is incom 
plete after overnight incubation (fragments are still visible), 
an additional 50 pl of the 20 mg/ml proteinase K solution is 
mixed in the solution and incubated for another night at 37° 
C. on a gently rocking or rotating platform. Following 
adequate digestion, one ml of a 6M NaCl solution is added 
to the sample and vigorously mixed. The resulting solution 
is centrifuged for 15 minutes at 3000 rpm. The pellet 
contains the precipitated cellular proteins, While the super 
natant contains the DNA. The supernatant is removed to a 15 
ml tube that contains 4 ml of isopropanol. The contents of 
the tube are mixed gently until the Water and the alcohol 
phases have mixed and a White DNA precipitate has formed. 
The DNA precipitate is removed and dipped in a solution of 
70% ethanol and gently mixed. The DNA precipitate is 
removed from the ethanol and air-dried. The precipitate is 
placed in distilled Water and dissolved. 
Kits for the extraction of high-molecular Weight DNA for 
PCR include a Genomic Isolation Kit A.S.A.P. (Boehringer 
Mannheim, Indianapolis, Ind.), Genomic DNA Isolation 
System (GIBCO BRL, Gaithersburg, Md.), Elu-Quik DNA 
Puri?cation Kit (Schleicher & Schuell, Keene, NH), DNA 
Extraction Kit (Stratagene, LaJolla, Calif.), TurboGen Iso 
lation Kit (Invitrogen, San Diego, Calif.), and the like. Use 
of these kits according to the manufacturer’s instructions is 
generally acceptable for puri?cation of DNA prior to prac 
ticing the methods of the present invention. 
The concentration and purity of the extracted DNA can be 
determined by spectrophotometric analysis of the absor 
bance of a diluted aliquot at 260 nm and 280 nm. After 
extraction of the DNA, PCR ampli?cation may proceed. The 
?rst step of each cycle of the PCR involves the separation of 
the nucleic acid duplex formed by the primer extension. 
Once the strands are separated, the next step in PCR 
involves hybridizing the separated strands With primers that 
?ank the target sequence. The primers are then extended to 
form complementary copies of the target strands. For suc 
cessful PCR ampli?cation, the primers are designed so that 
the position at Which each primer hybridizes along a duplex 
sequence is such that an extension product synthesized from 
one primer, When separated from the template (comple 
ment), serves as a template for the extension of the other 
primer. The cycle of denaturation, hybridization, and exten 
sion is repeated as many times as necessary to obtain the 
desired amount of ampli?ed nucleic acid. 
In a particularly useful embodiment of PCR ampli?cation, 
strand separation is achieved by heating the reaction to a 
su?iciently high temperature for a su?icient time to cause 
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the denaturation of the duplex but not to cause an irrevers 
ible denaturation of the polymerase (see US. Pat. No. 
4,965,188, incorporated herein by reference). Typical heat 
denaturation involves temperatures ranging from about 80° 
C. to 105° C. for times ranging from seconds to minutes. 
Strand separation, hoWever, can be accomplished by any 
suitable denaturing method including physical, chemical, or 
enzymatic means. Strand separation may be induced by a 
helicase, for example, or an enzyme capable of exhibiting 
helicase activity. For example, the enzyme RecA has heli 
case activity in the presence of ATP. The reaction conditions 
suitable for strand separation by helicases are knoWn in the 
art (see Kuhn Holfman-Berling, 1978, CSH-Quantitative 
Biology, 43163467; and Radding, 1982, Ann. Rev. Genetics 
16:405*436, each of Which is incorporated herein by refer 
ence. 
Template-dependent extension of primers in PCR is cata 
lyzed by a polymerizing agent in the presence of adequate 
amounts of four deoxyribonucleotide triphosphates (typi 
cally dATP, dGTP, dCTP, and dTTP) in a reaction medium 
comprised of the appropriate salts, metal cations, and pH 
bu?fering systems. Suitable polymerizing agents are 
enzymes knoWn to catalyze template-dependent DNA syn 
thesis. In some cases, the target regions may encode at least 
a portion of a protein expressed by the cell. In this instance, 
mRNA may be used for ampli?cation of the target region. 
Alternatively, PCR can be used to generate a cDNA library 
from RNA for further ampli?cation, the initial template for 
primer extension is RNA. Polymerizing agents suitable for 
synthesizing a complementary, copy-DNA (cDNA) 
sequence from the RNA template are reverse transcriptase 
(RT), such as avian myeloblastosis virus RT, Moloney 
murine leukemia virus RT, or Thermus lhermophilus (Tth) 
DNA polymerase, a thermostable DNA polymerase With 
reverse transcriptase activity marketed by Perkin Elmer 
Cetus, Inc. Typically, the genomic RNA template is heat 
degraded during the ?rst denaturation step after the initial 
reverse transcription step leaving only DNA template. Suit 
able polymerases for use With a DNA template include, for 
example, E. coli DNA polymerase I or its KlenoW fragment, 
T4 DNA polymerase, Tth polymerase, and Taq polymerase, 
a heat-stable DNA polymerase isolated from T hermus 
aqualicus and commercially available from Perkin Elmer 
Cetus, Inc. The latter enzyme is Widely used in the ampli 
?cation and sequencing of nucleic acids. The reaction con 
ditions for using Taq polymerase are knoWn in the art and are 
described in Gelfand, 1989, PCR Technology, supra. 
Allele Speci?c PCR 
Allele-speci?c PCR differentiates betWeen target regions 
differing in the presence of absence of a variation or poly 
morphism. PCR ampli?cation primers are chosen Which 
bind only to certain alleles of the target sequence. This 
method is described by Gibbs, Nucleic Acid Res. 
1711242742448 (1989). 
Allele Speci?c Oligonucleotide Screening Methods 
Further diagnostic screening methods employ the allele 
speci?c oligonucleotide (ASO) screening methods, as 
described by Saiki et al., Nature 3241634166 (1986). Oli 
gonucleotides With one or more base pair mismatches are 
generated for any particular allele. ASO screening methods 
detect mismatches betWeen variant target genomic: or PCR 
ampli?ed DNA and non-mutant oligonucleotides, shoWing 
decreased binding of the oligonucleotide relative to a mutant 
oligonucleotide. Oligonucleotide probes can be designed 
that under loW stringency Will bind to both polymorphic 
forms of the allele, but Which at high stringency, bind to the 
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allele to Which they correspond. Alternatively, stringency 
conditions can be devised in Which an essentially binary 
response is obtained, i.e., anASO corresponding to a variant 
form of the target gene Will hybridize to that allele, and not 
to the Wildtype allele. 
Ligase Mediated Allele Detection Method 
Target regions of a test subject’s DNA can be compared 
With target regions in una?fected and affected family mem 
bers by ligase-mediated allele detection. See Landegren et 
al., Science 241:107*1080 (1988). Ligase may also be used 
to detect point mutations in the ligation ampli?cation reac 
tion described in Wu et al., Genomics 4z560i569 (1989). 
The ligation ampli?cation reaction (LAR) utilizes ampli? 
cation of speci?c DNA sequence using sequential rounds of 
template dependent ligation as described in Wu, supra, and 
Barany, Proc. Nat. Acad. Sci. 88:189*193 (1990). 
Denaturing Gradient Gel Electrophoresis 
Ampli?cation products generated using the polymerase 
chain reaction can be analyzed by the use of denaturing 
gradient gel electrophoresis. Different alleles can be identi 
?ed based on the different sequence-dependent melting 
properties and electrophoretic migration of DNA in solution. 
DNA molecules melt in segments, termed melting domains, 
under conditions of increased temperature or denaturation. 
Each melting domain melts cooperatively at a distinct, 
base-speci?c melting temperature (TM). Melting domains 
are at least 20 base pairs in length, and may be up to several 
hundred base pairs in length. 
Differentiation betWeen alleles based on sequence speci?c 
melting domain differences can be assessed using polyacry 
lamide gel electrophoresis, as described in Chapter 7 of 
Erlich, ed., PCR Technology, Principles and Applications for 
DNA Ampli?cation, W.H. Freeman and Co., NeW York 
(1992), the contents of Which are hereby incorporated by 
reference. 
Generally, a target region to be analyzed by denaturing 
gradient gel electrophoresis is ampli?ed using PCR primers 
?anking the target region. The ampli?ed PCR product is 
applied to a polyacrylamide gel With a linear denaturing 
gradient as described in Myers et al., Meth. Enzymol. 
1551501527 (1986), and Myers et al., in Genomic Analysis, 
A Practical Approach, K. Davies Ed. IRL Press Limited, 
Oxford, pp. 95*139 (1988), the contents of Which are hereby 
incorporated by reference. The electrophoresis system is 
maintained at a temperature slightly beloW the Tm of the 
melting domains of the target sequences. 
In an alternative method of denaturing gradient gel elec 
trophoresis, the target sequences may be initially attached to 
a stretch of GC nucleotides, termed a GC clamp, as 
described in Chapter 7 of Erlich, supra. Preferably, at least 
80% of the nucleotides in the GC clamp are either guanine 
or cytosine. Preferably, the GC clamp is at least 30 bases 
long. This method is particularly suited to target sequences 
With high Tm’s. 
Generally, the target region is ampli?ed by the poly 
merase chain reaction as described above. One of the 
oligonucleotide PCR primers carries at its 5' end, the GC 
clamp region, at least 30 bases of the GC rich sequence, 
Which is incorporated into the 5' end of the target region 
during ampli?cation. The resulting ampli?ed target region is 
run on an electrophoresis gel under denaturing gradient 
conditions as described above. DNA fragments differing by 
a single base change Will migrate through the gel to different 
positions, Which may be visualized by ethidium bromide 
staining. 
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Temperature Gradient Gel Electrophoresis 
Temperature gradient gel electrophoresis (TGGE) is 
based on the same underlying principles as denaturing 
gradient gel electrophoresis, except the denaturing gradient 
is produced by differences in temperature instead of differ 
ences in the concentration of a chemical denaturant. Stan 
dard TGGE utilizes an electrophoresis apparatus With a 
temperature gradient running along the electrophoresis path. 
As samples migrate through a gel With a uniform concen 
tration of a chemical denaturant, they encounter increasing 
temperatures. An alternative method of TGGE, temporal 
temperature gradient gel electrophoresis (TTGE or tTGGE) 
uses a steadily increasing temperature of the entire electro 
phoresis gel to achieve the same result. As the samples 
migrate through the gel the temperature of the entire gel 
increases, leading the samples to encounter increasing tem 
perature as they migrate through the gel. Preparation of 
samples, including PCR ampli?cation With incorporation of 
a GC clamp, and visualization of products are the same as 
for denaturing gradient gel electrophoresis. 
Single-Strand Conformation Polymorphism Analysis 
Target sequences or alleles at the BPI locus can be 
differentiated using single-strand conformation polymor 
phism analysis, Which identi?es base differences by alter 
ation in electrophoretic migration of single stranded PCR 
products, as described in Orita et al., Proc. Nat. Acad. Sci. 
85z2766i2770 (1989). Ampli?ed PCR products can be gen 
erated as described above, and heated or otherWise dena 
tured, to form single stranded ampli?cation products. 
Single-stranded nucleic acids may refold or form secondary 
structures Which are partially dependent on the base 
sequence. Thus, electrophoretic mobility of single-stranded 
ampli?cation products can detect base-sequence difference 
betWeen alleles or target sequences. 
Chemical or Enzymatic Cleavage of Mismatches 
Differences betWeen target sequences can also be detected 
by differential chemical cleavage of mismatched base pairs, 
as described in Grompe et al., Am. J. Hum. Genet. 
48:212*222 (1991). In another method, differences betWeen 
target sequences can be detected by enzymatic cleavage of 
mismatched base pairs, as described in Nelson et al., Nature 
Genetics 4:11*18 (1993). Brie?y, genetic material from a 
patient and an affected family member may be used to 
generate mismatch free heterohybrid DNA duplexes. As 
used herein, “heterohybrid” means a DNA duplex strand 
comprising one strand of DNA from one person, usually the 
patient, and a second DNA strand from another person, 
usually an affected or una?fected family member. Positive 
selection for heterohybrids free of mismatches alloWs deter 
mination of small insertions, deletions or other polymor 
phisms that may be associated With alterations in androgen 
metabolism. 
Non-PCR Based DNA Diagnostics 
The identi?cation of a DNA sequence linked to BPI can 
be made Without an ampli?cation step, based on polymor 
phisms including restriction fragment length polymorphisms 
in a patient and a family member. Hybridization probes are 
generally oligonucleotides Which bind through complemen 
tary base pairing to all or part of a target nucleic acid. Probes 
typically bind target sequences lacking complete comple 
mentarity With the probe sequence depending on the strin 
gency of the hybridization conditions. The probes are pref 
erably labeled directly or indirectly, such that by assaying 
for the presence or absence of the probe, one can detect the 
presence or absence of the target sequence. Direct labeling 
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methods include radioisotope labeling, such as With 32P or 
358. Indirect labeling methods include ?uorescent tags, 
biotin complexes Which may be bound to avidin or strepta 
vidin, or peptide or protein tags. Visual detection methods 
include photoluminescents, Texas red, rhodamine and its 
derivatives, red leuco dye and e, e', 5, 5'-5354amethylben 
zidine (TMB), ?uorescein, and its derivatives, dansyl, 
umbelliferone and the like or With horse radish peroxidase, 
alkaline phosphatase and the like. 
Hybridization probes include any nucleotide sequence 
capable of hybridizing to the porcine chromosome Where 
BPI resides, and thus de?ning a genetic marker linked to 
BPI, including a restriction fragment length polymorphism, 
a hypervariable region, repetitive element, or a variable 
number tandem repeat. Hybridization probes can be any 
gene or a suitable analog. Further suitable hybridization 
probes include exon fragments or portions of cDNAs or 
genes knoWn to map to the relevant region of the chromo 
some. 
Preferred tandem repeat hybridization probes for use 
according to the present invention are those that recognize a 
small number of fragments at a speci?c locus at high 
stringency hybridization conditions, or that recognize a 
larger number of fragments at that locus When the stringency 
conditions are loWered. 
One or more additional restriction enzymes and/or probes 
and/ or primers can be used. Additional enzymes, constructed 
probes, and primers can be determined by routine experi 
mentation by those of ordinary skill in the art and are 
intended to be Within the scope of the invention. 
Although the methods described herein may be in terms 
of the use of a single restriction enzyme and a single set of 
primers, the methods are not so limited. One or more 
additional restriction enzymes and/or probes and/ or primers 
can be used, if desired. Additional enzymes, constructed 
probes and primers can be determined through routine 
experimentation, combined With the teachings provided and 
incorporated herein. 
Genetic markers for genes are determined as folloWs. 
Male and female animals of the same breed or breed cross 
or derived from similar genetic lineages are mated. The 
offspring With the bene?cial trait are determined. RFLP 
analysis of the parental DNA is conducted as discussed 
above in order to determine polymorphisms in the selected 
gene of each animal. The polymorphisms are associated With 
the traits. 
When this analysis is conducted and the polymorphism is 
determined by RFLP or other analysis, ampli?cation primers 
may be designed using analogous human or other closely 
related animal knoWn sequences. The sequences of many of 
the genes have high homology. Primers may also be 
designed using knoWn gene sequences as exempli?ed in 
Genbank or even designed from sequences obtained from 
linkage data from closely surrounding genes. According to 
the invention, sets of primers have been selected Which 
identify regions in polymorphic genes. The polymorphic 
fragments have been shoWn to be alleles, and each Was 
shoWn to be associated With bene?cial traits, such as disease 
resistance, for various breeds. Often genotype associated 
With this trait alternates for different breeds. This outcome is 
similar to the situation disclosed in Us. Pat. No. 5,374,523 
entitled “Allelic variants of Bovine Somatotropin gene: 
Genetic marker for Superior Milk Production in Bovine” 
Where the inventor found an allelic polymorphism in the 
somatotropin gene and one allelic form Was bene?cial for 
jersey coWs and the alternate form Was bene?cial for Hol 
stein coWs. 
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The reagents suitable for applying the methods of the 
invention may be packaged into convenient kits. The kits 
provide the necessary materials, packaged into suitable 
containers. At a minimum, the kit contains a reagent that 
identi?es a polymorphism in the selected gene that is 
associated With a trait. Preferably, the reagent is a PCR set 
(a set of primers, DNA polymerase and 4 nucleoside triph 
osphates) that hybridize With the gene or a fragment thereof. 
Preferably, the PCR set is included in the kit. Preferably, the 
kit further comprises additional means, such as reagents, for 
detecting or measuring the detectable entity or providing a 
control. Other reagents used for hybridization, prehybrid 
ization, DNA extraction, visualization etc. may also be 
included, if desired. 
The methods and materials of the invention may also be 
used more generally to evaluate animal DNA, genetically 
type individual animals, and detect genetic differences in 
animals. In particular, a sample of genomic DNA may be 
evaluated by reference to one or more controls to determine 
if a polymorphism in the gene is present. Preferably, RFLP 
analysis is performed With respect to the gene, and the 
results are compared With a control. The control is the result 
of a RFLP analysis of the gene of a different animal Where 
the polymorphism of the gene is knoWn. Similarly, the 
genotype of an animal may be determined by obtaining a 
sample of its mRNA or genomic DNA, conducting RFLP 
analysis of the gene in the DNA, and comparing the results 
With a control. Again, the control is the result of RFLP 
analysis of the same gene of a different animal. The results 
genetically type the pig by specifying the polymorphism in 
its selected gene. Finally, genetic differences among animals 
can be detected by obtaining samples of the mRNA or 
genomic DNA from at least tWo animals, identifying the 
presence or absence of a polymorphism in the gene, and 
comparing the results. 
These assays are useful for identifying the genetic mark 
ers relating to disease resistance, as discussed above, for 
identifying other polymorphisms in the gene that may be 
correlated With other characteristics, and for the general 
scienti?c analysis of genotypes and phenotypes. 
The genetic markers, methods, and kits of the invention 
are also useful in a breeding program to improve disease 
resistance in a breed, line, or population of animals. Con 
tinuous selection and breeding of animals that are at least 
heterozygous and preferably homozygous for a polymor 
phism associated With a bene?cial trait such as disease 
resistance Would lead to a breed, line, or population having 
higher numbers of offspring in each litter of the females of 
this breed or line. Thus, the markers are selection tools. 
The examples and methods herein disclose certain genes 
Which have been identi?ed to have a polymorphism Which 
is associated either positively or negatively With a bene?cial 
trait that Will have an effect on disease resistance of that 
animal. The identi?cation of the existence of a polymor 
phism Within a gene is often made by a single base alter 
native that results in a restriction site in certain allelic forms. 
A certain allele, hoWever, as demonstrated and discussed 
herein, may have a number of base changes associated With 
it that could be assayed for Which are indicative of the same 
polymorphism. Further, other genetic markers or genes may 
be linked to the polymorphisms disclosed herein so that 
assays may involve identi?cation of other genes or gene 
fragments, but Which ultimately rely upon genetic charac 
terization of animals for the same polymorphism. Any assay 
Which sorts and identi?es animals based upon the allelic 
differences disclosed herein are intended to be included 
Within the scope of this invention. 
US 7,070,929 B2 
19 
One of skill in the art, once a polymorphism has been 
identi?ed and a correlation to a particular trait established, 
Will understand that there are many Ways to genotype 
animals for this polymorphism. The design of such alterna 
tive tests merely represent optimization of parameters 
knoWn to those of skill in the art and are intended to be 
Within the scope of this invention as fully described herein. 
The markers are associated With innate immunity traits 
Which are non pathogen speci?c, so While bacteria is used 
for challenge it is expected that these traits Will improve 
animal health against a Wide variety of diseases or chal 
lenges such as stress, viral pathogen, etc. 
EXAMPLES 
Example 1 
Cloning, Sequencing, Polymorphism Identi?cation 
and Mapping of Porcine Bactericidal Permeability 
Increasing Protein (BPI) Gene 
Total RNA Was isolated from the pig spleen and ?rst 
strand cDNA synthesis Was performed. Partial porcine BPI 
cDNA Was isolated by RT-PCR using the primers designed 
from the homology sequences of human and bovine BPI 
cDNA. Using sequence comparison of RT-PCR products 
from different lines, several single nucleotide polymor 
phisms (SNPs) Were observed. To develop DNA-based PCR 
detection, tWo pig speci?c primer pairs Were designed for 
the region of exon 4 and 5, and the region of exon 10 and 
exon 11 based on pig BPI cDNA sequence. Then tWo sets of 
PCR-RFLPs (exon 4 and intron, and exon 10 and intron) 
markers Were developed to perform population studies and 
conduct association analyses betWeen BPI variation and pig 
disease resistance phenotypes. An about 300 base pair 
insertion/deletion polymorphism Was also observed in intron 
10. Using pig speci?c primers and PCR-RFLP markers, BPI 
Was physically and linkage mapped to the pig chromosome 
17. 
Biology of BPI 
Bactericidal/permeability-increasing protein (BPI) is a 
neutrophil granular pattern recognition molecule Which has 
bactericidal activity on gram-negative bacteria (Elsbach and 
Weiss, 1998; Ho?fmann et al., 1999). The cDNA sequence of 
BPI has been elucidated in several species, including human 
(Gray et al., 1989) and bovine (Leong et al., 1990) (but not 
pig), and the structure of human BPI gene has been analyZed 
(Hubacek et al., 1997). The crystal structure of human BPI 
shoWed that BPI consists of tWo functionally distinct 
domains: a potently antibacterial and anti-endotoxin amino 
terminal domain and a carboxy-terminal portion that imparts 
opsonic activity to BPI (Elsbach et al., 1998). 
Neutrophils in human neWborns are de?cient in BPI and 
the de?ciency correlates With decreased antibacterial activ 
ity of neWborn neutrophils (Levy et al., 1999). Levy et al. 
(2000) has developed a recombinant BPI peptide (rBPI23) to 
be tested as a drug to increase neWborn innate immunology. 
This rBPI23, Which consists of the Nh2-terminal portion of 
BPI, has been shoWn by in vivo studies (Nell et al (2000); 
see also papers discussed in revieW by Elsbach and Weiss, 
1998) and ex vivo studies (Levy et al 2000) to contain 
anti-bacterial properties primarily through binding of the 
lipid A portion of lipopolysaccaride (LPS). On the other 
hand, the C-terminal portion has been shoWn to increase BPI 
protein stability (BuloW et al., 2000) as Well as the opsoniZa 
tion of bacteria by neutrophils or monocytes in an in vitro 
model (Iovine et al, 1997). 
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A 23 kDa NH2-terminal fragment of human BPI (rBPI23) 
has been administered to LPS-treated pigs (Vandermeer et 
al., 1994). rBPI23 treatment had no effect on some immune 
responses (including serum TNF-alpha or thromboxane A2 
levels), but did improve several negative effects in the lung 
associated With exposure to LPS such as alveolitis, hypox 
emia, and pulmonary edema. Also, the increased expression 
of opsonin receptors on circulating phagocytes in response 
to LPS Was decreased by rBPI23 administration (Vander 
meer et al., 1994). 
On the other hand, macrophage expressing BPI-IgG 
fusion protein Were resistant to endotoxin (LPS) treatment 
and shoWed a decrease in the secretion of TNF-alpha (Dahl 
berg et al., 1996); a dampening effect on TNF-alpha pro 
duction in response to LPS Was also observed With human 
monocytes and in other systems (revieWed in Elsbach and 
Weiss, 1998). Thus the lack of an effect on TNF-alpha 
induction in pigs is contrary to BPI effects in other species, 
and may re?ect either differences in species or in experi 
mental conditions. Human BPI is believed to have activity 
against several gram-negative bacteria, and several bacterial 
species have been directly tested and shoWn to be suscep 
tible to BPI protein; including several Salmonella species 
such as Salmonella minnesola (Ooi et al., 1991) and Sal 
monella Zyphimurium et al., 1995). 
BPI Genetics 
There have been tWo reports of genetic variability at the 
human BPI locus. Hollings and Gray (1994) reported the 
presence of a restriction fragment length polymorphism at 
human BPI, Which Was detected by Southern hybridiZation. 
This polymorphism Was not localiZed Within human BPI. 
Another polymorphism, detected by PstI digestion of a large 
PCR product, Was also reported for human BPI (Hubacek et 
al. 1997). This polymorphism Was mapped to intron 5, 
although speci?c sequence differences Were not reported at 
this polymorphism. Using physical mapping techniques, 
BPI gene Was assigned to human chromosome 20 (Gray et 
al., 1993). 
TWo batches of animals Were experimentally challenged 
With salmonella, and infection related measurements Were 
taken for 7 days post infection. Novel tests for polymor 
phisms at BPI Were used to genotype the challenged ani 
mals. Association analysis revealed statistical association of 
BPI genotype With innate immune traits such as fecal 
bacteria counts, as Well as several measures of immune cell 
numbers, during the challenge. Controlling fecal bacterial 
counts has economic value as an infected animal is the main 
source of transmission to healthy animals. Thus a marker 
that Would identify animals With decreased fecal bacterial 
counts Would be valuable and have utility. 
Genetic Information and Marker Technology for variability 
at the BPI Gene 
Set 1 (BPI-AvaII) 
Primer sequences 
Forward: GGT GGC AAC TTT GAC CTG AG (SEQ ID NO:l) 
Reverse:CAT CGG AGG TCT CTG GAC AAG (SEQ ID NO:2) 
Ampli?cation annotations. This primer pair ampli?es a 
540 bp product containing 153 bp exon 4 and 387 bp intron 
4 of the porcine BPI gene. 
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PCR Conditions 
Mg++conc 1.5 mM, dNTPs-conc 200.0 uM, Taq 0.375U 
Cycle pro?le 95 C for 3 min; 40><[94c for 45s; 55 C for 45s; 
72 C for 1 min] 72 C for 5 min. 
PCR-Annotation. Ampli?cation Was performed using 25 
ng of genomic DNA and 0.5 uM of each primer in a reaction 
volume of 10 pl. 
PCR-RFLP markers 
Alleles detected by PCR-RFLP markers 
Size of 
Recognition Fragments 
Enzyme Allele site base (base pairs) 
Avall 1 103 G 417, 123 
2 103 A 540 
Polymorphism atposition 103 is detected by AvaIl digestion and by using 
2.5% agarose gel. 
Chromosome location. BPI Was physically located on pig 
chromosome 17(1/2) q21eq23 by using pig/rodent somatic 
cell hybrid panel (SCHP) comprising 27 cell lines. Linkage 
mapping from Avall genotyping of PiGMaP reference fami 
lies shoWed that the most possible gene order With BPI on 
pig chromosome 17 Was S0204-8.6-S0359-3.1-SW1031 
15.4-BPl-10.3-SW840. 
Allele frequencies. Allele C3 (Avall digestion) Was 
observed With a frequency of 100% in Yorkshire (n:9), 
Hampshire (n:6), Duroc (n:8), Landrace (n:8), Large White 
(n:11) and Wild boar n:2). Allele C3 Was detected With a 
frequency of 31.25% in Meishan (n:16) and 93.75% in a 
partially related commercial population. The sequence 
ampli?ed is shoWn in FIG. 1 (SEQ ID N013) sequence does 
not include primer sequences) 
Note: a) Bold text are exon 4 sequences and regular text are 
intron sequences. 
b) RIA or G. 
Set 11 (BPl-Hpall) 
Primer sequence 
Forward CCC AAC ATG GAG ATG CAG TTC (SEQ ID NO:4) 
primer: 
Reverse CAA TGA ATC AAT GAG CAC ACC (SEQ ID NO:5) 
primer: 
Ampli?cation annotation. This primer pair ampli?es a 
445 bp product containing 153 bp exon 10 and 292 bp intron 
10 of the porcine BPI gene. 
PCR Conditions 
Mg++conc 1.5 mM, dNTPs-conc 200.0 uM, Taq 0.375U 
Cycle pro?le 95 C for 3 min; 40><[94c for 45s; 60 C for 45s; 
72 C for 45s], 72 C for 5 min. 
PCR-Annotation. Ampli?cation Was performed using 25 ng of 
genomic DNA and .5 ;M of each primer in a reaction volume of 10 ll. 
Alleles detected by PCR-RFLP markers 
Recognition 
Enzyme Allele site base fragments 
HpaII 3 122 T 445 
4 122 G 304, 142 
Polymorphism at position 122 is detected by Hpall digestion and by using 
2.5% agarose gel. 
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Allele frequencies Allele 3 (Hpall digestion) Was 
observed With a frequency of 93.67% in a partially related 
commercial population (n:79). The ampli?ed sequence is 
shoWn in FIG. 2 SEQ ID NO: 6, Sequence (not including 
primer sequences). 
Note: a) Bold text are exon 10 sequences and regular text are 
intron sequences. 
b) KIG or T. 
Set 111 (BPl-Length polymorphism) 
Primer sequence 
Forward: CCC AAC ATG GAG ATG CAG TTC (SEQ ID NO:4) 
Reverse:AAG CCT TTT GGA CCG GAC AC (SEQ ID NO:7) 
Ampli?cation annotations. This primer pair ampli?es a 
1309 bp product containing 153 bp exon 10, 1110 bp intron 
10 and 46 bp intron 11 of the porcine BPI gene. 
PCR Conditions 
Mg++conc 1.5 mM, dNTPs-conc 200.0 uM, Taq 0.375U 
Cycle pro?le 95 C for 3 min; 40><[94 C for 1 min; 60 C 
for 1 min; 72 C for 1.5 min] 72 C for 5 min. 
PCR-Annotation. Ampli?cation Was performed using 25 
ng of genomic DNA and 0.5 uM of each primer in a reaction 
volume of 10 pl. 
Length polymorphism. A length polymorphism Was 
observed betWeen 1309 bp fragment (Allele 5) and about 
1600 bp fragment (Allele 6). 
Allele frequencies allele 5 Was observed With a frequency 
of 13.86% in a partially related commercial population 
(n:83). 
Sequences (not including primer sequences) is shoWn in 
FIG. 3 SEQ ID N018. 
Note: a) Bold text are exon 10 and exon 11 sequences and 
regular text are intron sequences. 
b) III represent about 300 bp insertion present in allele 6. 
This inserted sequence is a repetitive region that is 
difficult to sequence accurately. 
Additional novel porcine BPI sequence information: Full 
length coding region sequence of porcine BPI and alignment 
of full-length sequence of each allele (3,4) at the DNA level 
and the protein level. This cDNA sequence Was obtained by 
using novel primers to amplify BPI cDNA fragments from 
mRNA converted to cDNA. Partially overlapping cDNA 
fragments Were then sequenced to determine the complete 
sequence. The result is depicted in FIGS. 4a (nucleotide) and 
4b (amino acid). 
Example 1 
Bacterial Challenge and Association Testing 
Summary 
To test the marker assays to identify animals differing for 
innate immunity traits, tWo batches of animals Were experi 
mentally challenged With Salmonella cholerasuis and infec 
tion related measurements Were taken post infection. Three 
different polymorphism tests at the BPI gene (BPI Ava ll, 
BPI Hpa ll, BPl-LP) Were used to classify challenged 
animals, and all three assigned animals to classes Which 
shoWed signi?cant differences for innate immunity as shoWn 
by fecal shedding of bacteria at the end of the challenge 
(FMPND6). In many cases, additional traits related to the 
immune system such as: the number of neutrophils, mono 
cytes or White blood cells at the end of the challenge; the 
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difference in these cell numbers, as well as lymphocytes, at 
the beginning of the challenge versus the end were also 
statistically associated with speci?c BPl genotypes. The 
percentage of neutrophils or lymphocytes at either the 
beginning or end of the challenge was also associated with 
BPl genotypes. 
lmportantly, the BPl Hpall genetic test identi?es animals 
with different BPl proteins because the sequence of the 
individual Hpa ll alleles show different protein sequences 
are encoded by the different BPl Hpall alleles. The BPl 
protein is important in the early response to gram-negative 
bacterial infection, thus an association of BPl genotypes 
with fecal shedding at the end of the challenge is consistent 
with an altered function of BPl in these classes of animals. 
Controlling fecal bacterial counts has economic value as 
an infected animal is the main source of transmission of the 
disease to healthy animals. Thus a marker that would 
identify animals with decreased fecal bacterial counts would 
be valuable and have utility. 
Protocol 
Pregnant sows were pre-selected based on data from 
preliminary BPl1 genotype analysis and a crude in vitro 
macrophage bactericidal assay results. From these sows, two 
separate experiments of 42 piglets (8*19 days old) were 
derived and piglets shipped to isolation facilities. Piglets 
consisted of 2 lines of pigs from two different farms. Piglets 
were determined to be Salmonella-free by frequent bacterial 
culture of fecal material. Piglets were divided into principals 
and controls and grown to 7*9 weeks of age prior to 
intranasal challenge with 1 billion colony forming units of 
Salmonella choleraesuis X3246. The control group (saline 
inoculated) consisted of 1 piglet/litter (Exp #1, n:13; Exp 
#2, n:12). The principal group (Salmonella infected) con 
sisted of 2 or 3 piglets/litter (Exp #1, n:29; Exp #2, n:30). 
Following challenge, animals were monitored daily for 
temperature, clinical signs and Salmonella shedding (quali 
tative and quantitative). Pigs were necropsied post S. chol 
eraesuis or saline inoculation and quantitative bacteriology 
(most probable number) was performed on ileocecal lymph 
node and from fecal samples at the end of the challenge. 
Blood samples were drawn at speci?c intervals during 
challenge and standard complete blood count (CBC) were 
performed. Portions of mesenteric lymph node, spleen, liver, 
lung, and muscle were collected and froZen in liquid nitro 
gen for DNA analysis. Results are shown in Tables Ex1-1 to 
Exl-3, and genotype frequencies within this challenge popu 
lation for each of the markers is shown in Table Ex1-4. 
Statistical Treatment of Data 
Phenotypic and genotype data were available on 59 
challenged animals from lines A and B (15 and 44 respec 
tively). See Table Ex1-4 for genotype frequencies. Three 
markers in BPl were genotyped. 
Least square means were estimated for the 3 genotype 
classes from the following model: 
Trait:sow id+experiment+barn+genotype 
with sowid as random effect and experiment and barn as 
?xed elfects. Signi?cance p-values for genotype were also 
recorded from this model. 
Results and Discussion 
Overall results are summarized in Tables Ex1-1-3. The 
data were log transformed for the following traits: all 
bacterial counts, as well as macro1, macro2, mono2 and 
wbc1, because of the non-normal distribution of the data. 
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Log transformation is a widely accepted treatment for non 
normally distributed data sets. 
Statistical association is de?ned as a comparison between 
phenotype and genotype that show a P value less that 0.1; 
i.e., a statistical term that indicates the declared statistically 
signi?cant difference between classes being compared has a 
con?dence of greater than 90% of being correct. Several 
associations have even higher levels of con?dence, such as 
P values less than 0.05 or even less than 0.01 (see individual 
Results in Tables below). 
As can be seen from the data, BPl genotypes determined 
by all BPl marker systems were associated with differences 
in fecal bacterial counts (FMPND6; fecal bacterial count on 
day 6 of challenge). The data also shows that BPl genotypes, 
determined by one or more BPl markers, are associated with 
several innate immune defense parameters. These param 
eters are critical for control of and recovery from infection, 
and include fever (temperature) and numbers of immune 
cells before and after infection. Some alleles are found to be 
associated with traits in only one of the analyses, often due 
to lack of informativeness of the marker. 
TABLE Ex1-1 
BPI Avall genotype association analysis in example 1. 
Line A 
LS Means (s.e.)** 
Trait* 11 12 22 P value 
tempD7 40.4 (.18) c 41.1 (.29) d i 0.08 
FMPND6 .44 (1.1) g 1.84 (1.1) h i 0.006 
neutl 8.76 (.70) 8.00 (.91) i .42 
neut2 7.56 (2.6) e 2.68 (2.8) f i .02 
neutidiff —1.17 (2.8) g —5.35 (2.9) h i .008 
monol 1.17 (.29) 1.42 (.36) i .45 
mono2 .37 (.13) c .09 (.15) d i .05 
monoidiff 1.51 (.80) e —.34 (.89) f i .02 
wbcl 1.31 (.04) 1.25 (.05) i .31 
wbc2 22.7 (2.9) c 16.5 (3.4) d i .06 
wbcidiff 2.10 (3.5) a —2.3 (4.1) b i .21 
*Traits are: TEMPDO = temperature on day 0 of challenge, TEMPDl 
temperature on day 1 after challenge, etc; ICLND7 = Salmonella count in 
ileocecal lymph node on day 7 post challenge; FMPND6 = mean fecal 
Salmonella count on day 6 after challenge; Macro 1 and 2 = macrophage 
numbers before (1) and after (2) challenge; Macroidi?“ = difference in 
macrophage numbers before and after challenge; lymph 1, 2, diff = lym 
phocyte numbers before (1) and after (2)challenge and the difference 
between these values; pneut1,2, diff = percentage of neutrophils before (1) 
and after (2) challenge and the difference between these values; plymph 1, 
2, diff = percentage of lymphocytes before (1) and after (2) challenge and 
the difference between these values. 
**Signi?cant diiferences (p values) for LS means are indicated as follows: 
aib p <.30 
041 p <.10 
eff p <.05 
gih p <.01 
kil p <.001 
















